RPRX
Royalty Pharma Plc
NASDAQ: RPRX · HEALTHCARE · BIOTECHNOLOGY
$49.49
-0.10% today
Updated 2026-04-29
Market cap
$29.37B
P/E ratio
27.83
P/S ratio
12.35x
EPS (TTM)
$1.78
Dividend yield
1.77%
52W range
$31 – $50
Volume
3.2M
Royalty Pharma Plc (RPRX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $244000.00 | — | — | — | $0.00 | $1.65B | $1.88B | $1.60B | $1.79B | $1.81B | $2.12B | $2.29B | $2.24B | $2.35B | $2.26B | $2.38B |
| Revenue growth (YoY) | — | — | — | — | — | -100.0% | — | — | — | — | +13.6% | -14.9% | +12.3% | +1.1% | +17.0% | +7.9% | -2.3% | +5.2% | -3.9% | +5.1% |
| Cost of revenue | — | — | $25.59M | $26.44M | $5.10M | — | — | — | $0.00 | $0.00 | $0.00 | $33.27M | $135.96M | $1.02B | $230.84M | $452.84M | $904.24M | $560.66M | $732.46M | $3.85M |
| Gross profit | — | — | — | — | — | — | — | — | $0.00 | $1.65B | $1.88B | $1.60B | $1.79B | $1.81B | $2.12B | $2.29B | $2.24B | $2.35B | $2.26B | $2.38B |
| Gross margin | — | — | — | — | 0.0% | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $11.91M | $12.42M | $22.57M | $23.06M | $2.90M | $8.68M | $13.34M | $22.91M | $27.11M | $98.38M | $91.02M | $117.87M | $392.61M | $83.04M | $26.29M | $200.08M | $177.11M | $52.00M | $2.00M | $452.00M |
| SG&A | $14.77M | $15.17M | — | — | — | $12.38M | $18.00M | $27.47M | $32.50M | $29.18M | $17.32M | $106.44M | $61.91M | $103.44M | $181.72M | $182.83M | $227.30M | $249.75M | $236.67M | $573.48M |
| Operating income | — | — | — | — | — | — | — | — | $-32.54M | $794.28M | $722.87M | $939.69M | $1.36B | $2.62B | $1.60B | $1.43B | $307.06M | $1.49B | $1.29B | $1.56B |
| Operating margin | — | — | — | — | 0.0% | — | — | — | — | 48.1% | 38.5% | 58.8% | 76.0% | 144.6% | 75.2% | 62.5% | 13.7% | 63.4% | 57.1% | 65.6% |
| EBITDA | — | — | — | — | — | — | — | — | — | $862.44M | $1.07B | $1.62B | $1.83B | $2.75B | $1.88B | $1.43B | $423.69M | $1.89B | $1.56B | $1.64B |
| EBITDA margin | — | — | — | — | 0.0% | — | — | — | — | 52.2% | 56.9% | 101.6% | 102.0% | 151.8% | 88.7% | 62.5% | 18.9% | 80.2% | 68.8% | 68.8% |
| EBIT | — | — | — | — | — | — | — | — | $-32.53M | $794.28M | $1.00B | $1.59B | $1.80B | $2.73B | $1.86B | $1.41B | $418.02M | $1.49B | $1.29B | $1.63B |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $224.42M | $238.91M | $247.34M | $279.96M | $268.57M | $157.06M | $166.14M | $187.96M | $187.19M | $225.51M | $307.66M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | — | — | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | — | — | — | — | — | — | — | — | $-32.53M | $581.43M | $565.91M | $1.21B | $1.38B | $2.35B | $975.04M | $619.73M | $42.83M | $1.13B | $858.98M | $770.95M |
| Net income growth (YoY) | — | — | — | — | — | — | — | — | — | +1887.1% | -2.7% | +113.8% | +13.9% | +70.5% | -58.5% | -36.4% | -93.1% | +2549.5% | -24.3% | -10.2% |
| Profit margin | — | — | — | — | 0.0% | — | — | — | — | 35.2% | 30.1% | 75.7% | 76.8% | 129.4% | 45.9% | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% |